Avalon announces patent issuance for CAR-T, CAR-NK tech in Hong Kong

Avalon (ALBT) GloboCare announced the issuance of a new standard patent by the Hong Kong Intellectual Property Department for its proprietary CAR-T and CAR-Natural Killer cell technology. Granted based on a Chinese patent and issued as Patent No. HK40074322, the Certificate of Invention represents a significant milestone in Avalon’s global intellectual property strategy. The 20-year patent term, effective February 21, 2020, provides long-term protection for the Company’s proprietary CAR-T and CAR-Natural Killer cell technology innovations in the Hong Kong Special Administrative Region. Co-developed and co-owned with Avalon’s strategic partner Arbele Limited, based in Hong Kong, this patent advances Avalon’s positioning in chimeric antigen receptor-based cell therapies. It complements the Company’s existing patent protections in the United States and other jurisdictions under the Patent Cooperation Treaty. The patented technology is designed to enhance the manufacturing, expansion, survival, and therapeutic efficacy of CAR-T and CAR-NK cells including: Bispecific Anti-CD19xCD22 CAR Design: Targets both CD19 and CD22 antigens expected to reduce the risk of tumor escape via antigen loss, a common challenge in hematologic malignancies. Localized Cytokine Induction: Intended to activate immune responses specifically at tumor sites, expected to improve CAR cell proliferation, cytotoxicity, and persistence while also attempting to stimulate the patient’s own immune system.